Allegheny Health Network

Running trials

• Recruiting

  HeartBeam ECG Registry

  NCT07501299· Source

• Recruiting

  Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

  NCT07337590· Source

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184944· Phase 3· Source

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07185009· Phase 3· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Source

• Active, not recruiting

  Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

  NCT07120945· Source

• Recruiting

  A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

  NCT06971614· Phase 2· Source

• Enrolling by invitation

  Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

  NCT06560021· Source

• Active, not recruiting

  A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  NCT06095128· Phase 4· Source

• Recruiting

  AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

  NCT06063850· Phase 1/2· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Source

• Recruiting

  A Registry for People With Lung Cancer

  NCT06424327· Source

• Active, not recruiting

  A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  NCT06045754· Phase 4· Source

• Active, not recruiting

  Real-world Safety and Effectiveness Registry of Catheter Ablation of Paroxysmal Atrial Fibrillation as Initial Control Therapy With the Thermocool SmartTouch SF Catheter (A Sub-study of REAL AF Registry)

  NCT07092774· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Source

• Recruiting

  MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

  NCT06050707· Phase 2· Source

• Recruiting

  A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

  NCT06057935· Phase 2· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Source

• Recruiting

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  NCT05579366· Phase 1/2· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Source

• Active, not recruiting

  Study of INCB123667 in Subjects With Advanced Solid Tumors

  NCT05238922· Phase 1· Source

• Active, not recruiting

  CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

  NCT05306288· Source

• Active, not recruiting

  Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

  NCT05081193· Phase 2· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Source

• Recruiting

  Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

  NCT04998669· Phase 2· Source

• Recruiting

  RA-PRO PRAGMATIC TRIAL

  NCT04692493· Phase 3· Source

• Active, not recruiting

  Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT04781088· Phase 2· Source

• Recruiting

  Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  NCT04606914· Phase 2· Source

• Active, not recruiting

  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· Phase 3· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Source

• Recruiting

  Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  NCT04427384· Source

• Active, not recruiting

  Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

  NCT04142437· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Source

• Active, not recruiting

  Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  NCT04146051· Phase 2· Source

• Recruiting

  The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

  NCT04075305· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Source

• Recruiting

  The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  NCT03142152· Source

• Recruiting

  Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

  NCT04088071· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Ovarian cancer4 recruiting
• Colorectal cancer3 recruiting
• Crohn's disease3 recruiting
• Ulcerative colitis3 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Glioblastoma2 recruiting
• Mesothelioma2 recruiting
• Multiple myeloma2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

  NCT06123130· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Source

• Completed

  A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

  NCT05601128· Phase 3· Source

• Completed

  A Clinical Utility Study of PrismRA for Rheumatoid Arthritis

  NCT05161234· Source

• Completed

  DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

  NCT04825834· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Source

• Terminated

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  NCT04203160· Phase 1/2· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Source

• Completed

  Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

  NCT03632135· Phase 3· Source

• Completed

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Source

Trial sites

• Allegheny Health Network44 trials
• ALLEGHENY HEALTH NETWORK (Data Collection Only)2 trials
• Allegheny Health Network (Site 0042)1 trial
• Allegheny Health Network- Site Number : 84000581 trial
• Allegheny Health Network - West Penn1 trial
• The Allegheny Health Network (AHN) Center for Digestive Health-Site Number: 84001074 trials
• Allegheny Health Network2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Endometrial cancer17 works · 4 trials